ESMO Symposium on Signalling Pathways in Cancer 2015

Oncology Meeting Resources

13 Mar - 14 Mar, Barcelona, Spain

Signalling Pathways 2014 square

The 2015 Symposium concentrated on targeting the MAPK pathway: from RAS to MEK. The programme covered preclinical data and genetics relevant for the understanding of the functional mechanisms in the RAS/ERK/MEK pathway, regulation of MAPK signalling, the rationale and strategies to inhibiting the pathway, biomarkers, mechanisms of resistance, as well as how to overcome it, and some important interactions with other pathways.

On this page, ESMO members may view the slide sets and webcasts of presentations given at the ESMO Symposium on Signalling Pathways in Cancer 2015 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Useful links

Presenter Presentation title Session title
Yossi Yarden Signalling networks: The RAS-ERK pathway in context Signalling networks: The RAS-ERK pathway in context
Manuela Baccarini Historical overview: How the knowledge of the RAS-RAF-MEK-ERK pathway has developed over the years Basic biology, genetics and mouse models
Mariano Barbacid Mouse model of RAS-driven lung and pancreatic cancer Basic biology, genetics and mouse models
Aldo Scarpa The genomic landscape of RAS-driven tumours Basic biology, genetics and mouse models
Richard Marais BRAF and NRAS signalling in melanoma: Basic biology and clinical exploitation Regulation of signalling pathway and therapeutic targeting
Julian Downward Activation of PI3K from RAS Regulation of signalling pathway and therapeutic targeting
Udai Banerji Direct targeting of RAS / small molecules Regulation of signalling pathway and therapeutic targeting
Caroline Robert Combination with translation inhibitors Therapeutic targeting, mechanisms of resistance and overcoming resistance
Teresa Troiani The role of MET in resistance Therapeutic targeting, mechanisms of resistance and overcoming resistance
Pierre Laurent-Puig Biomarkers of primary resistance to targeted therapies Therapeutic targeting, mechanisms of resistance and overcoming resistance
Caroline Robert Melanoma (BRAF, NRAS) Clinical therapeutic application in cancer
Jean-Yves Douillard Colorectal cancer (RAS, BRAF) Clinical therapeutic application in cancer
Solange Peters NSCLC (BRAF) Clinical therapeutic application in cancer
Egbert Smit NSCLC (KRAS) Clinical therapeutic application in cancer
Jordi Rodón Early phase studies with drugs targeting the pathway Development of novel drugs targeting the pathway